These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 4895428)

  • 21. 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) in the treatment of malignant tumors other than melanoma.
    Kingra GS; Comis R; Olson KB; Horton J
    Cancer Chemother Rep; 1971 Jun; 55(3):281-3. PubMed ID: 5115849
    [No Abstract]   [Full Text] [Related]  

  • 22. Drug trials in neuroblastoma: cyclophosphamide (NSC-26271) alone; vincristine (NSC-67574) plus cyclophosphamide; 6-mercaptopurine (NSC-755) plus 6-methylmercaptopurine riboside (NSC-40774); and cytosine arabinoside (NSC-63878) alone.
    Starling KA; Sutow WW; Donaldson MH; Land VJ; Lane DM
    Cancer Chemother Rep; 1974; 58(5 Pt 1):683-8. PubMed ID: 4426047
    [No Abstract]   [Full Text] [Related]  

  • 23. The current status of cancer chemotherapy for selected human neoplasms.
    Rubin RN
    Clin Ther; 1981; 4(2):74-94. PubMed ID: 7028265
    [No Abstract]   [Full Text] [Related]  

  • 24. [Medical treatment of cancer in the elderly].
    Bangerter M; Heinrich B; Brudler O
    MMW Fortschr Med; 2004 Sep; 146(40):30-2. PubMed ID: 15529665
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical trial of cisplatin in advanced malignancies.
    Qiao SM
    Chin Med J (Engl); 1982 Aug; 95(8):557-64. PubMed ID: 6814856
    [No Abstract]   [Full Text] [Related]  

  • 26. Clinical trials referral resource. Clinical trials with taxol.
    Cheson BD
    Oncology (Williston Park); 1992 Mar; 6(3):67-70. PubMed ID: 1348954
    [No Abstract]   [Full Text] [Related]  

  • 27. Day care for cancer patients.
    Ratkowski E; Liebermann R; Hochman A
    JAMA; 1974 Oct; 230(3):430-1. PubMed ID: 4369905
    [No Abstract]   [Full Text] [Related]  

  • 28. Chemotherapy of solid tumours.
    World Health Organ Tech Rep Ser; 1977; (605):1-106. PubMed ID: 407727
    [No Abstract]   [Full Text] [Related]  

  • 29. [Study of the action of antitumor compounds on primary explants from human tumors].
    Navashin SM; Fomina IP; Osokina LI; Zharikov AA
    Antibiotiki; 1967 Sep; 12(9):803-7. PubMed ID: 4171894
    [No Abstract]   [Full Text] [Related]  

  • 30. Phase I study of L-asparaginase (NSC 109229).
    Wilson WL; Weiss AJ; Ramirez G
    Oncology; 1975; 32(3-4):109-17. PubMed ID: 768851
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dianhydrogalactitol (NSC-132313): phase II study in solid tumors.
    de Jager R; Brugarolas A; Hansen H; Cavalli F; Ryssel H; Siegenthaler P; Clarysse A; Renard J; Kenis Y; Alberto P
    Eur J Cancer (1965); 1979 Jul; 15(7):971-4. PubMed ID: 385328
    [No Abstract]   [Full Text] [Related]  

  • 32. [The use of cyclophosphamide in antineoplastic therapy].
    Cugini A; Sosso A
    Minerva Med; 1966 May; 57(42):1914-21. PubMed ID: 5949443
    [No Abstract]   [Full Text] [Related]  

  • 33. Treatment of small cell lung cancer with 6-mercaptopurine: a phase II study.
    Hansen SW; Skovsgaard T; Sørensen JB
    Cancer Treat Rep; 1985 May; 69(5):555. PubMed ID: 2988775
    [No Abstract]   [Full Text] [Related]  

  • 34. [1st clinical experiences with isophosphamide. Long-term results of 2 therapeutic approaches].
    Pigatto JC
    Prensa Med Argent; 1971 Oct; 58(32):1618-21. PubMed ID: 4943249
    [No Abstract]   [Full Text] [Related]  

  • 35. [Effect of 4-methyluracil on the antineoplastic and toxic effect of 6-mercaptopurine].
    Pol'kina RI
    Vopr Onkol; 1971; 17(1):86. PubMed ID: 5108359
    [No Abstract]   [Full Text] [Related]  

  • 36. CDA deficiency as a possible culprit for life-threatening toxicities after cytarabine plus 6-mercaptopurine therapy: pharmacogenetic investigations.
    Ciccolini J; Evrard A; M'Batchi L; Pourroy B; Mercier C; Iliadis A; Lacarelle B; Verschuur A; Ouafik L; André N
    Pharmacogenomics; 2012 Mar; 13(4):393-7. PubMed ID: 22379997
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The influence of site of metastasis on tumour growth and response to chemotherapy.
    Slack NH; Bross ID
    Br J Cancer; 1975 Jul; 32(1):78-86. PubMed ID: 1174452
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Evaluation of the serum lysozyme level as a further parameter for predicting hematological tolerance in patients treated with cytostatic chemotherapy. Study of 134 cases].
    Neretto G; Agricola R; Giovanelli E; Poccardi G; Pellerito R; Furno F; Martinetto P; Pellegrino S; Daglio C; Tondolo M
    Recenti Prog Med; 1980 Oct; 69(4):431-57. PubMed ID: 7006015
    [No Abstract]   [Full Text] [Related]  

  • 39. Effects of mitomycin c (NSC-26980) in 346 patients with advanced cancer. Eastern Clinical Drug Evaluation Program.
    Moore GE; Bross ID; Ausman R; Nadler S; Jones R; Slack N; Rimm AA
    Cancer Chemother Rep; 1968 Oct; 52(6):675-84. PubMed ID: 5753587
    [No Abstract]   [Full Text] [Related]  

  • 40. The paradigm of personalized therapy in oncology.
    Gasparini G; Longo R
    Expert Opin Ther Targets; 2012 Mar; 16 Suppl 1():S7-16. PubMed ID: 22073968
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.